The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes.

Trial Profile

The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary) ; Gamma aminobutyric acid
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Oct 2017 According to a Diamyd Medical media release, to date 74 patients have been enrolled in this trial and 41 of them have completed the entire trial.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 According to a Diamyd Medical media release, to date 68 patients have been enrolled in this trial and 31 of them have completed the entire trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top